Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lupin Limited ( (IN:LUPIN) ) has provided an announcement.
Lupin Limited announced that it has received approval from the U.S. FDA for its biosimilar product, Armlupeg (pegfilgrastim-unne), marking its first biosimilar approval. This product, intended to decrease infection incidence in certain cancer patients and increase survival in radiation-exposed patients, will be manufactured at Lupin’s Pune facility. The approval signifies a significant step in Lupin’s strategy to provide affordable and accessible medicines in the U.S., enhancing its biosimilar portfolio and strengthening its market position. The biosimilar market is lucrative, with the pegfilgrastim market alone valued at USD 1,295 million annually in the U.S., indicating potential for substantial revenue growth and impact on stakeholders.
More about Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company holds a strong market position in India and the U.S.
Average Trading Volume: 23,003
Technical Sentiment Signal: Strong Buy
Current Market Cap: 950.5B INR
Learn more about LUPIN stock on TipRanks’ Stock Analysis page.